P01 CA95426/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2004	3
2005	5
2006	5
2007	8
2008	10
2009	9
2010	14
2011	7
2012	12
2013	5
2014	9
2015	12
2016	2
2024	0

1

Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.

Riches JC, Ramsay AG, Gribben JG. Riches JC, et al. Curr Pharm Des. 2012;18(23):3389-98. doi: 10.2174/138161212801227023. Curr Pharm Des. 2012. PMID: 22591385 Review.

2

Signalling to drug resistance in CLL.

Hertlein E, Byrd JC. Hertlein E, et al. Best Pract Res Clin Haematol. 2010 Mar;23(1):121-31. doi: 10.1016/j.beha.2010.01.007. Best Pract Res Clin Haematol. 2010. PMID: 20620976 Review.

3

Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.

Luedke E, Jaime-Ramirez AC, Bhave N, Carson WE 3rd. Luedke E, et al. J Immunother. 2012 Jun;35(5):367-73. doi: 10.1097/CJI.0b013e3182562d76. J Immunother. 2012. PMID: 22576341 Free PMC article. Review.

4

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC. Awan FT, et al. Leuk Lymphoma. 2010 Jan;51(1):27-38. doi: 10.3109/10428190903350405. Leuk Lymphoma. 2010. PMID: 20055657 Free PMC article. Review.

5

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. Jaglowski SM, et al. Blood. 2010 Nov 11;116(19):3705-14. doi: 10.1182/blood-2010-04-001230. Epub 2010 Jul 7. Blood. 2010. PMID: 20610811 Free PMC article. Review.

6

The B-cell receptor signaling pathway as a therapeutic target in CLL.

Woyach JA, Johnson AJ, Byrd JC. Woyach JA, et al. Blood. 2012 Aug 9;120(6):1175-84. doi: 10.1182/blood-2012-02-362624. Epub 2012 Jun 19. Blood. 2012. PMID: 22715122 Free PMC article. Review.

7

Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.

Gowda A, Byrd JC. Gowda A, et al. Curr Opin Hematol. 2006 Jul;13(4):266-72. doi: 10.1097/01.moh.0000231425.46148.b0. Curr Opin Hematol. 2006. PMID: 16755224 Review.

8

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC. Kohrt HE, et al. Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869. Blood. 2014. PMID: 24652965 Free PMC article. No abstract available.

9

Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.

Herman SE, Johnson AJ. Herman SE, et al. Clin Cancer Res. 2012 Aug 1;18(15):4013-8. doi: 10.1158/1078-0432.CCR-11-1402. Epub 2012 Jun 18. Clin Cancer Res. 2012. PMID: 22711705 Free PMC article. Review.

10

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Maddocks KJ, et al. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. JAMA Oncol. 2015. PMID: 26182309 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year